SL Consulting LLC

SL Consulting LLC was paid $11.55M by Medicaid between Jan 2018 and Dec 2024, across 79 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 29% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Nevada

Rank by total paid#3 of 31

Median peer was paid$269K

This provider vs. median43×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	12,800	$550K
2019	29,917	$725K
2020	37,076	$1.13M
2021	71,765	$2.44M
2022	92,181	$3.17M
2023	72,509	$1.88M
2024incomplete	73,180	$1.66M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	29%	50,481	33,734	$3.38M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	26%	19,544	12,999	$2.97M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	15%	47,033	15,740	$1.79M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	11%	57,791	38,440	$1.26M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.3%	10,514	7,366	$261K
87481		1.9%	11,362	8,531	$224K
87653		1.9%	11,300	8,499	$215K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.1%	3,025	2,318	$128K
87511		1.0%	4,070	2,745	$117K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	3,797	2,722	$115K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	4,307	2,796	$115K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	4,247	2,778	$114K

67 more codes

87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	3,411	$98K
87486		<1%	8,649	$95K
87631		<1%	7,701	$89K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	30,759	$83K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	2,248	$83K
87581		<1%	8,365	$77K
87541		<1%	8,364	$76K
87532		<1%	5,401	$50K
87496		<1%	5,400	$50K
87640		<1%	5,407	$50K
87563		<1%	1,236	$34K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	611	$15K
80053	Comprehensive metabolic panel	<1%	9,399	$13K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	10,054	$11K
82248		<1%	9,441	$7K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	750	$6K
80050	General health panel	<1%	489	$5K
80048	Basic metabolic panel (calcium, ionized)	<1%	3,648	$4K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	761	$4K
80061	Lipid panel	<1%	1,558	$3K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,625	$2K
83735		<1%	2,173	$2K
84443	Thyroid stimulating hormone (TSH)	<1%	1,890	$2K
84134		<1%	559	$2K
86140		<1%	1,252	$1K
87086	Culture, bacterial; quantitative colony count, urine	<1%	959	$1K
84439		<1%	937	$1K
83721		<1%	1,072	$1K
84481		<1%	559	$1K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	172	$935.58
80069		<1%	882	$886.91
80202		<1%	417	$856.46
84145		<1%	218	$712.53
85651		<1%	1,151	$708.80
82607		<1%	547	$678.48
87070		<1%	417	$670.32
86800		<1%	356	$618.45
82746		<1%	339	$451.35
36415	Collection of venous blood by venipuncture	<1%	13,645	$398.18
80164		<1%	213	$379.25
87075		<1%	237	$342.38
82728		<1%	180	$260.40
81001		<1%	502	$222.48
83540		<1%	253	$171.16
82977		<1%	111	$150.90
80177		<1%	45	$126.70
85610		<1%	315	$110.29
83550		<1%	150	$109.94
86141		<1%	91	$105.96
84100		<1%	196	$104.34
81005		<1%	447	$102.12
87040		<1%	91	$84.60
84432		<1%	28	$76.72
84153		<1%	65	$75.30
87205		<1%	90	$72.75
84550		<1%	173	$55.44
80076		<1%	66	$50.13
82565		<1%	79	$38.50
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	3,491	$29.00
81007		<1%	115	$23.10
85652		<1%	18	$20.35
85018		<1%	168	$14.58
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	1,844	$10.83
82140		<1%	18	$9.94
84480		<1%	35	$9.67
84436		<1%	49	$9.38
85027		0%	65	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCHAUDHARI, SMITA (MANAGING MEMBER)